StockWatch
·
SUDARSHAN CHEMICAL INDUSTRIES LTD. · QQ2 FY-2027 · THE CALL

Integration gains offset by margin collapse, RIECO drag persists

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsSUDARSCHEMSUDARSHAN CHEMICAL INDUSTRIES LTD.16 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Q1 beat sparked no guidance lift; Q2 weakness forced defensive reaffirmation. RIECO integration delays and cost overruns hint at execution friction.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Sudarshan is mid-integration with strong legacy-business momentum (H1 +22% revenue, 15.6% EBITDA) but severe near-term headwinds: Q2 PAT collapsed -70.5% QoQ to 1.1% NPM, RIECO acquisition dragging (negative EBITDA), and macro uncertainty (US housing, European construction weak). Management reaffirmed EUR 700M/EUR 35M EBITDA guidance defensively but credibility is mixed given operational challenges. Long-term 7× EBITDA target is ambitious but lacks near-term de-rating risk.

₹2742.6 Cr

Revenue · +14.9% YoY

₹30.5 Cr

Reported PAT · +58% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

H1 Legacy business revenue grew 22%, EBITDA 36.5%

MET

H1 FY27 Legacy: INR 1,636 Cr (22% YoY), EBITDA INR 243 Cr (36.5% YoY growth) — supported

EBITDA 15.6% margin H1 at Legacy level

MET

INR 243 Cr EBITDA / ~INR 1,551 Cr revenue = 15.7% — accurate

Acquired Group consistent performance, strong value capture underway

OVERSTATED

Acquired Group H1 INR 3,935 Cr revenue, 6.1% EBITDA margin but RIECO negative (INR -3 Cr EBITDA Q2) — partially contradicted

Total pigment global business showing healthy EBITDA: INR 242 Cr

MISS

INR 242 Cr EBITDA / INR 2,695 Cr revenue = 9% margin, down from INR 327 Cr (prior) — margin declining, contradicts health narrative

Q2 FY27 delivered strong growth; external challenges being navigated

OVERSTATED

Revenue +14.9% YoY but PAT +58% YoY masks -70.5% QoQ PAT collapse (30.5 Cr); NPM 1.1% signals severe margin compression — overstated

Earnings quality

What changed since the last call

Deltas vs. the prior call

RIECO integration hitting headwinds

Downgrade

Q1 showed 6.1% EBITDA margin; Q2 RIECO negative. Supply chain, execution delays cited. Cost synergies lagging vs. guidance assumptions.

Guidance stance: defensive reaffirmation

Neutral

EUR 700M/EUR 35M EBITDA 'reaffirmed, no revision' despite Q1 beat and Q2 challenges. Phrasing signals caution, not confidence in upside.

VP4 divestiture closure (post-quarter)

New

EUR 75.8M non-core asset sale for debt reduction. Not included in Q2 results; signals balance-sheet focus over growth capex.

Customer trust recovery in progress

Upgrade

Management claims lost market share from Heubach insolvency being regained; destocking scenario ongoing but expected to ease.

The Q&A

Analysts pressed hard on cost synergies (Q1 guidance implied 12% EBITDA margin, Q2 delivered ~9%) and inventory docking. Management partially dodged specific cost-reduction numbers, cited integration work in progress, defended guidance as conservative. Tone: analytical pressure but not hostile; management held line on guidance.

The exchanges that mattered

Revenue growth drivers — Nitesh Dhoot, Nomura

Answered

About half-and-half price vs. volume. Some volume growth in Acquired Group but muted. Lost sales across industries being regained; process underway but will take time.

EBITDA margin bridge — Nitesh Dhoot, Nomura

Partial

VP4 sale factored out; this is first normal two, three quarter. Keeping guidance because it is experience with this business. External situation very challenging, geopolitical uncertainties.

Heubach EBITDA improvement levers — Niharika

Answered

Two aspects: strong value capture in operations, purchase-org structure. Using backward integration, AI leverage, cost synergies. Inventory destocking from customers ongoing but expected over, not forever.

VP4 deal and cash deployment — Viraj Mahadevia, Jefferies

Dodged

Board looking at all options. Transformation completed; now looking at how to use cash for better shareholder returns. No immediate plans but will decide in a year's time.

Cost synergy realization timeline — Rohit, Goldman Sachs

Partial

Absolutely. Manufacturing and procurement work underway. Backward integration, AI still leveraging. 300-400 basis points swing on margins with backward integration and AI implementation possible. Should bridge margin.

Acquired Group EUR 35M EBITDA feasibility — Arch Verma, DAM Capital

Answered

Manufacturing cost reduction, procurement, yield improvements across sites. IT integration with backward-integration projects ongoing; second use of AI still leveraging. Scope for 300 bps swing on margins. Backward integration not done; can win some volumes.

Guidance

Forward guidance and management's confidence

FY27 Acquired Group EUR 700M turnover (reaffirmed)

Medium

Guidance unchanged from prior call; macro caution cited (US housing, European construction weak). No upside lift despite Q1 beat.

Long-term: 7× 2023 EBITDA by FY29 (~₹1,400+ Cr total EBITDA)

Medium

Mechanism: cost synergies (manufacturing, procurement, backward integration, SAP, AI), value capture, market-share recovery. Timeline FY29; credibility hinges on RIECO turnaround and macro stabilization.

300-400 basis points margin swing possible from backward integration, AI, cost reduction

Low

Management cited this in Q&A but offered no timeline. Current total pigment EBITDA margin 9%; targeting 12-13% implied by 7× EBITDA guidance, but no explicit margin target stated.

EUR 35M Acquired Group EBITDA (reaffirmed, 5% of EUR 700M revenue)

Low

RIECO Q2 negative EBITDA, supply-chain issues, integration delays undermine confidence. Reaffirmation appears defensive, not based on updated assumptions.

Risks the call surfaced

Ranked by how much they should concern a holder

Execution risk (integration)

High

SAP integration only 2 of 130 applications live; backward-integration projects not fully commercialized yet. RIECO negative EBITDA Q2 signals slow progress on synergies. Cost reduction targets (300-400 bps margin swing) dependent on completion.

Macro headwinds (demand weakness)

High

Management explicitly cited US housing and European construction as weak. Masterbatch demand volatile due to oil prices. Customer destocking ongoing (demand 'mute'). These segments represent majority of Acquired Group revenue.

Guidance credibility (EUR 35M EBITDA)

High

EUR 35M EBITDA target for Acquired Group (5% margin on EUR 700M) looks stretched given RIECO negative Q2 and Q2 total pigment EBITDA margin only 9% despite integration benefits claimed. Reaffirmation described as defensive ('cautiously navigating'), not based on updated numbers.

Q2 profitability cliff

High

PAT collapsed to ₹30.5 Cr (1.1% NPM) despite +14.9% YoY revenue growth and positive EBITDA momentum. Project cost overruns cited but unquantified. Unclear if one-time or structural; suggests operational distress not reflected in forward guidance.

Market-share recovery pace (Heubach legacy)

Medium

During Heubach insolvency, Sudarshan lost significant market share and customer trust. Management claims recovery 'underway' but timeline vague ('some time to build that up'). Regaining depends on operational stability and cost competitiveness, both still unproven.

Management

Score 7/10. Clear on structure and progress (integration, SAP, backward integration), but evasive on specific cost numbers and PAT collapse detail. Transparent on challenges (macro, RIECO, destocking) but defensive on guidance credibility. Mixed. H1 Legacy business +22% revenue, +36.5% EBITDA growth demonstrates strong standalone execution. But Acquired Group integration hits headwinds: RIECO negative Q2, SAP 2/130 live, cost synergies lagging (9% margin vs. expected 12%+). Q2 PAT -70.5% QoQ unexplained fully.

What to watch next
  • 1 · Q3 FY27 (Oct-Dec 2026)

    Macro stabilization in US/Europe; customer destocking resolution

  • 2 · FY27-end (Mar 2027)

    RIECO turnaround visible; SAP integration phases 1 & 2 complete

  • 3 · FY28-FY29

    7× 2023 EBITDA trajectory; backward-integration projects yielding cost leverage

Long-term 7× EBITDA target is ambitious but lacks near-term de-rating risk.

Informational and educational content only. Not investment advice.